ArticleObesity (Silver Spring, Md.)2023
Use and continuity of weight-modifying medications among adults with diabetes and overweight/obesity: US population study.
Article in Obesity (Silver Spring, Md.), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Weight Changes With Tirzepatide and Concomitant Weight-Inducing Medications: Post Hoc Analysis of Randomized Clinical Trials.JAMA network open · 2026Pooled it
- The New Obesity Treatment Landscape: Challenges and Opportunities to Promote Shared Decision-Making in People With Obesity and Type 2 Diabetes.Diabetes care · 2026Review
- Pharmacologic treatment of obesity in adults: Standards of care in overweight and obesity.BMJ open diabetes research & care · 2026Review
- Improvement in body mass index category was associated with improved cardiometabolic measures and patient-reported outcomes in adults with type 2 diabetes treated with tirzepatide.Diabetes, obesity & metabolism · 2025Article
- Attitudes towards different weight loss approaches among adults with type 2 diabetes and obesity.Patient education and counseling · 2025Article
- Glycaemic and Weight Control in People Aged 65 or Younger Newly Diagnosed with Type 2 Diabetes in Spain: Insights from the PRIORITY-T2D Study.Advances in therapy · 2025Observational
- Factors Associated With Semaglutide Initiation Among Adults With Obesity.JAMA network open · 2025 · on this mapObservational
- 1. Improving Care and Promoting Health in Populations: Standards of Care in Diabetes-2025.Diabetes care · 2025Review
- 8. Obesity and Weight Management for the Prevention and Treatment of Type 2 Diabetes: Standards of Care in Diabetes-2025.Diabetes care · 2025Review
- Tirzepatide in Hispanic/Latino Patients With Type 2 Diabetes: A Subgroup Analysis of the SURPASS Program.The Journal of clinical endocrinology and metabolism · 2024Article
Corrections and comments
- Commented on by
Authors and funding
5 authors.
Funding
Abstract
objectiveTrends in use and continuity of use of diabetes-specific and non-diabetes weight-reducing (WR), weight-inducing (WI), and weight-neutral (WN) medications were examined among US adults with diabetes and overweight/obesity.
methodsSerial cross-sectional data from Medical Expenditure Panel Surveys (2010-2019) for adults (≥18 years) with diabetes and BMI ≥27 kg/m
resultsAmong 7402 US adults with diabetes and overweight/obesity (mean age 60.0 years [SD 13], 50% female), 64.9% of participants used any WI medications, decreasing from 68.9% (95% CI: 64.3%-73.5%) in 2010 to 58.6% (95% CI: 54.7%-62.5%) in 2019. It was estimated that 13.5% used WR medications, increasing 3.31-fold, from 6.4% (95% CI: 4.1%-8.7%) to 21.2% (95% CI: 18.0%-24.4%) and that 73.1% used WN medications, ranging from 70.5% (95% CI: 66.5-74.6) to 75.0% (95% CI: 71.7%-78.4%). Among adults using diabetes-specific WI (53.7%), WR (7.1%), and WN (62.4%) medications during the first year, 7.3%, 16.4%, and 9.0% discontinued it in the second year, respectively.
conclusionsOver 2010-2019, 64.9% of adults with diabetes and overweight/obesity were treated with WI medications, 13.5% with WR medications, and 73.1% with WN medications. Discontinuation of WR medications was nearly twice that of WI medications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.